智通财经APP获悉,Juvena Therapeutics宣布与礼来(LLY.US)合作开发并向全球市场推出旨在增强肌肉健康的新候选药物。
根据协议,Juvena将获得预付款、股权投资以及基于研发与商业化进展的额外里程碑款项。
作为协议的一部分,Juvena将向礼来提供主要候选药物的独家权利,而礼来将负责进一步研究、开发和商业化。
智通财经APP获悉,Juvena Therapeutics宣布与礼来(LLY.US)合作开发并向全球市场推出旨在增强肌肉健康的新候选药物。
根据协议,Juvena将获得预付款、股权投资以及基于研发与商业化进展的额外里程碑款项。
作为协议的一部分,Juvena将向礼来提供主要候选药物的独家权利,而礼来将负责进一步研究、开发和商业化。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.